How many drugs treat Bacterial infection of skin?

Drug Landscape tracks 10 marketed treatments for Bacterial infection of skin (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bacterial-infection-of-skin.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bacterial infection of skin — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bacterial infection of skin (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bacterial infection of skin, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Nuzyra	OMADACYCLINE TOSYLATE	Paratek Pharms	Tetracycline-class Antibacterial [EPC]		2018-01-01
Nuzyra	OMADACYCLINE	Paratek Pharms	Tetracycline-class Antibacterial [EPC]		2018-01-01
Baxdela	DELAFLOXACIN	Melinta	Fluoroquinolone Antibacterial		2017-01-01
Dalvance	DALBAVANCIN	AbbVie	Lipoglycopeptide Antibacterial		2014-01-01
Orbactiv	ORITAVANCIN	Melinta Therap	Lipoglycopeptide Antibacterial		2014-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Chlorocidin	CHLORAMPHENICOL	Parkedale	Amphenicol-class Antibacterial	Cytochrome P450 3A4	1950-01-01
Orbactiv	Orbactiv	Melinta Therapeutics, LLC
Xydalba	Xydalba	Correvio International Sarl

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Bacterial infection of skin
Merck & Co. · 2 drugs in Bacterial infection of skin
Paratek Pharms · 2 drugs in Bacterial infection of skin
Melinta · 1 drug in Bacterial infection of skin
Melinta Therap · 1 drug in Bacterial infection of skin
Melinta Therapeutics, LLC · 1 drug in Bacterial infection of skin
Parkedale · 1 drug in Bacterial infection of skin
AbbVie · 1 drug in Bacterial infection of skin
Correvio International Sarl · 1 drug in Bacterial infection of skin

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bacterial infection of skin:

Cite this brief

Drug Landscape (2026). Bacterial infection of skin — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bacterial-infection-of-skin. Accessed 2026-06-10.

Bacterial infection of skin full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing